Global Legionella Testing Market - 2022-2029

Global Legionella Testing Market - 2022-2029

Market Overview

Legionella Testing Market is expected to grow at a CAGR of 9.7% during the forecasting period (2022-2029).

Legionella is a bacterium that causes a severe form of pneumonia called Legionnaires disease or flu-like illness. Legionella testing aids in detecting the presence of bacteria to help diagnose the cause of a person's pneumonia.

Market Dynamics

The major driving forces are the rising incidence of pneumonia and legionella-related illnesses, increasing demand for rapid and advanced diagnostic techniques, and technological advancements in bacterial testing.

The increasing awareness and growing spending on research and development are driving the global market growth.

The growing awareness and increased investment in healthcare are fueling global market growth. For instance, Western Region Public Health Training Center is involved in providing training for Preventing Legionnaires’ Disease: A Training over Legionella Water Management Programs, which is developed by the CDC’s National Center for Environmental Health, Immunization and Respiratory Diseases, National Network of Public Health Institutes, College of the Public Health University of Arizona Mel and Enid Zuckerman and The Western Region Training Center at the University of Arizona. Furthermore, the increasing investment in healthcare is also fueling the global market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, in 2000, the production from the pharmaceutical industries contributed €127,504 million to Europe's economy, which reached €199,730 million in 2010, €293,213 million in 2019 and €310,000 million in 2020. Furthermore, the R&D expenditure was €17,849 million in 2000, €27,920 million in 2010, €37,754 million in 2019 and €39,000 million in 2020.

The high costs associated with the tests and strict government laws will restrain the global Legionella Testing growth.

The insufficient disposable income in developing and underdeveloped countries, issues in sensitivity of diagnostic tests, high costs associated with the tests, and strict government laws. The high costs associated with the tests will likely hamper the market growth. For instance, typical costs range from £200.00 for a small dental or GP practice to £500.00 for a medium-sized care home. The presence of strict government laws is also hindering the market. For instance, The Control of Substances Hazardous to Health Regulations (COSHH) gives a framework of actions to control the risk from a range of hazardous substances, including biological agents (e.g., Legionella) - to identify and evaluate the risk and implement any necessary measures to control any risk. Since the L8 Approved Code of Practice (3rd edition) (ACOP) was published, there has been a requirement for landlords of both business premises and domestic premises to evaluate the risks from exposure to Legionella to their tenants.

Industry analysis.

The global legionella testing report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing Etc.

COVID-19 Impact Analysis

Different restrictions and regulations forced to prevent further COVID-19 infection spread have impacted the global market since, making it difficult for people to perform legionella testing affecting the market. Furthermore, the pandemic has also affected many developed and developing countries economies, making it difficult for the legionella testing market to grow during the outburst.

Segment Analysis/B>

Urinary antigen testing is expected to have a large share of the Legionella Testing market during the forecast period (2022-2029).

The Urinary Antigen Test segment is expected to grow rapidly over the forecast period (2022-2029). UAT is a diagnostic tool that offers same-day results. Further, UAT is not resource-specific and technically intensive like the culture tests. Since the urinary antigen test does not require respiratory fluid samples, sensitivity issues are also reduced. Thus, UAT remains the test of choice for clinicians and diagnostic experts primarily because of its ease of handling, rapid testing advantage, increased sensitivity, and specificity. For instance, according to the CDC, it has 70–100% sensitivity and 95-100% specificity. Also, the presence of research and development activities on urinary antigen tests is driving the market. Furthermore, a research study on the novel Legionella urinary antigen test kit for diagnosing Legionella pneumonia showed that it could detect Legionella pneumonia caused by non-L. pneumophila serogroup.

Geographical Analysis

North America is dominating the global legionella testing market.

North America dominated the global legionella testing market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the rising incidence of legionellosis and the presence of key players in the region. For instance, according to the Occupational Safety and Health Administration, around 6,000 Legionnaires' disease cases are reported annually in the United States. U.S. population-based study estimated that 8,000-18,000 people are hospitalized yearly with Legionnaires' disease. Furthermore, most market key players have a large portion of the global market, such as Becton, Dickinson and Company, Idexx Laboratories Inc., Phigenics LLC, Thermo Fisher Scientific Inc. and Abbott, ensure that North America commands the global legionella testing market. Moreover, North America has the most advanced and robust healthcare infrastructure and better healthcare cost reimbursement policies.

Competitive Landscape

The major players operating in the global legionella testing market are Albagaia Ltd, Aquacert Ltd, Becton, Dickinson and Company, BioMerieux SA, Idexx Laboratories Inc., Merck Millipore, Pacific Water Technology, Phigenics LLC, Abbott, Qiagen NV, and Thermo Fisher Scientific Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the legionella testing market globally. For instance, on February 23, 2022, Thermo Fisher Scientific Inc. and Moderna entered a long-term collaboration.

Abbott

Overview:

Abbott Laboratories is a leading American healthcare and medical devices innovator and producer headquartered in Illinois, United States, established in 1888. Abbott Laboratories is currently involved in dealing with medical devices, diagnostics, branded generic medicines and nutritional products.

Product Portfolio:

The product portfolio of Abbott for Legionella Testing has BINAX™ LEGIONELLA URINARY ANTIGEN EIA, Etc.

The global legionella testing report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.